Insmed (INSM) Competitors $143.50 -1.80 (-1.24%) Closing price 04:00 PM EasternExtended Trading$143.16 -0.34 (-0.24%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock INSM vs. GSK, TAK, ARGX, ONC, BNTX, TEVA, SMMT, GMAB, VTRS, and RDYShould you be buying Insmed stock or one of its competitors? The main competitors of Insmed include GSK (GSK), Takeda Pharmaceutical (TAK), argenex (ARGX), BeOne Medicines (ONC), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Viatris (VTRS), and Dr. Reddy's Laboratories (RDY). These companies are all part of the "pharmaceutical products" industry. Insmed vs. Its Competitors GSK Takeda Pharmaceutical argenex BeOne Medicines BioNTech Teva Pharmaceutical Industries Summit Therapeutics Genmab A/S Viatris Dr. Reddy's Laboratories Insmed (NASDAQ:INSM) and GSK (NYSE:GSK) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation, earnings and media sentiment. Do analysts recommend INSM or GSK? Insmed presently has a consensus price target of $134.79, suggesting a potential downside of 6.07%. GSK has a consensus price target of $37.38, suggesting a potential downside of 5.04%. Given GSK's higher probable upside, analysts clearly believe GSK is more favorable than Insmed.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Insmed 0 Sell rating(s) 1 Hold rating(s) 16 Buy rating(s) 0 Strong Buy rating(s) 2.94GSK 1 Sell rating(s) 6 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.86 Which has stronger earnings and valuation, INSM or GSK? GSK has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInsmed$363.71M83.40-$913.77M-$5.71-25.13GSK$40.10B2.00$3.29B$2.1618.22 Is INSM or GSK more profitable? GSK has a net margin of 10.81% compared to Insmed's net margin of -259.82%. GSK's return on equity of 49.22% beat Insmed's return on equity.Company Net Margins Return on Equity Return on Assets Insmed-259.82% -195.37% -49.49% GSK 10.81%49.22%11.31% Which has more volatility and risk, INSM or GSK? Insmed has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500. Comparatively, GSK has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500. Do insiders & institutionals have more ownership in INSM or GSK? 15.7% of GSK shares are held by institutional investors. 3.0% of Insmed shares are held by company insiders. Comparatively, 10.0% of GSK shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Does the media refer more to INSM or GSK? In the previous week, GSK had 6 more articles in the media than Insmed. MarketBeat recorded 19 mentions for GSK and 13 mentions for Insmed. Insmed's average media sentiment score of 1.47 beat GSK's score of 0.80 indicating that Insmed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 11 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GSK 11 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryGSK beats Insmed on 11 of the 16 factors compared between the two stocks. Get Insmed News Delivered to You Automatically Sign up to receive the latest news and ratings for INSM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INSM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INSM vs. The Competition Export to ExcelMetricInsmedMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$28.77B$3.12B$5.77B$9.77BDividend YieldN/A2.28%6.66%4.49%P/E Ratio-25.1321.1082.3726.60Price / Sales83.40408.88536.82175.38Price / CashN/A43.5325.7028.92Price / Book24.288.1310.646.56Net Income-$913.77M-$53.35M$3.28B$266.04M7 Day Performance6.67%0.45%-0.08%-0.58%1 Month Performance32.03%9.94%10.36%6.24%1 Year Performance95.76%11.73%49.00%22.21% Insmed Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INSMInsmed3.6681 of 5 stars$143.50-1.2%$134.79-6.1%+90.0%$28.77B$363.71M-25.131,271Positive NewsAnalyst ForecastGSKGSK2.5148 of 5 stars$39.68-1.3%$37.38-5.8%-11.4%$80.85B$31.63B18.3768,629Dividend CutTAKTakeda Pharmaceutical2.4621 of 5 stars$15.08-2.8%N/A+1.8%$47.98B$30.09B50.2747,455ARGXargenex3.9874 of 5 stars$677.32+2.6%$757.88+11.9%+36.6%$41.45B$3.05B34.731,599Analyst ForecastONCBeOne Medicines0.7938 of 5 stars$308.63-1.6%$330.89+7.2%N/A$33.83B$3.81B-178.4011,000BNTXBioNTech1.912 of 5 stars$105.07-5.2%$135.80+29.2%+14.1%$25.26B$2.98B-65.676,772Positive NewsTEVATeva Pharmaceutical Industries3.4916 of 5 stars$18.14-1.7%$24.71+36.2%-0.5%$20.81B$16.63B-113.3836,830News CoveragePositive NewsSMMTSummit Therapeutics3.1726 of 5 stars$26.27+0.3%$32.85+25.0%+83.7%$19.51B$700K-26.01110Analyst ForecastOptions VolumeGMABGenmab A/S3.9479 of 5 stars$24.31-1.4%$37.60+54.7%-6.9%$15.60B$3.12B12.222,682News CoveragePositive NewsGap UpVTRSViatris1.7768 of 5 stars$10.55-0.9%$10.40-1.4%-12.6%$12.30B$14.74B-3.6432,000RDYDr. Reddy's Laboratories2.7269 of 5 stars$14.46-0.4%$16.95+17.3%-15.5%$12.07B$3.81B21.9027,811Positive News Related Companies and Tools Related Companies GSK Competitors Takeda Pharmaceutical Competitors argenex Competitors BeOne Medicines Competitors BioNTech Competitors Teva Pharmaceutical Industries Competitors Summit Therapeutics Competitors Genmab A/S Competitors Viatris Competitors Dr. Reddy's Laboratories Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INSM) was last updated on 9/3/2025 by MarketBeat.com Staff From Our PartnersHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredThe Orphaned Well Crisis Hidden Across AmericaAcross the U.S., millions of abandoned oil and gas wells are leaking methane into the air — a costly and dange...The Tomorrow Investor | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Coin Could Explode, and it’s Hiding in Plain Sight!The #1 coin with skyrocket potential right now... Sometimes the biggest opportunities are hiding in plain s...Crypto 101 Media | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Insmed, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Insmed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
